These findings underscore the potential of 14-3-3 proteins not only as biomarkers for disease stratification and prognosis but also as targets for personalized medicine, where treatments could be tailored to the patient’s specific 14-3-3 profile, potentially improving clinical outcomes in bone and joint diseases. Here, YWHAQ is linked to arthropathy.